T1	MajorClaim 1 162	A combination of mitoxantrone plus prednisone is preferable to prednisone alone for reduction of pain in men with metastatic, hormone-resistant, prostate cancer.
T2	Premise 992 1058	At 6 weeks, both groups showed improvement in several HQL domains,
T3	Premise 1063 1187	only physical functioning and pain were better in the mitoxantrone-plus-prednisone group than in the prednisone-alone group.
T4	Premise 1188 1447	After 6 weeks, patients taking prednisone showed no improvement in HQL scores, whereas those taking mitoxantrone plus prednisone showed significant improvements in global quality of life (P =.009), four functioning domains, and nine symptoms (.001 < P <. 01),
T6	Premise 1452 1568	the improvement (> 10 units on a scale of 0 to100) lasted longer than in the prednisone-alone group (.004 < P <.05).
T7	Premise 1569 1768	The addition of mitoxantrone to prednisone after failure of prednisone alone was associated with improvements in pain, pain impact, pain relief, insomnia, and global quality of life (.001 < P <.003).
T8	Claim 1769 1945	Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone.
R1	Support Arg1:T8 Arg2:T1	
R2	Support Arg1:T2 Arg2:T8	
R3	Support Arg1:T3 Arg2:T8	
R4	Support Arg1:T6 Arg2:T8	
R5	Support Arg1:T4 Arg2:T8	
R6	Support Arg1:T7 Arg2:T1	
